相关实验视频
Updated: Sep 16, 2025

Methods for Detecting Cough and Airway Inflammation in Mice
Published on: August 2, 2024
现实世界的使用和对fefapixant的反应在耐火性慢性咳中
Hisako Matsumoto1, Yoshihiro Kanemitsu2, Motoki Ohe3
1Department of Respiratory Medicine and Allergology, Kindai University Faculty of Medicine, Osaka, Japan.
作为P2X3抗剂的Gefapixant显示出对耐火性慢性咳的实际有效性. 许多患者经历了显著的咳减缓,通常在两周内就会出现改善.
科学领域:
- 药理学 药理学是指药理学的学科.
- 呼吸系统医学 呼吸系统医学
- 临床试验 临床试验
背景情况:
- 耐火性慢性咳 (RCC) 显著影响生活质量.
- P2X3抗剂fefapixant代表了RCC的新型治疗类.
- 现实世界关于fefapixant在RCC中的疗效的数据有限.
研究的目的:
- 评估fefapixant在RCC患者的实际使用和有效性.
- 确定与治疗反应和停止治疗相关的因素.
主要方法:
- 在272名RCC患者的多中心回顾性研究中,Fefapixant被处方.
- 数据收集包括人口统计,咳特征,治疗反应和味觉障碍.
- 咳专家评估了患者的反应和停药后的咳过程.
主要成果:
- 一半的患者报告了显著的咳反应 (≥5/10级),其中25%报告了出色的反应 (≥8/10).
- 改善速度很快,通常在2周内,并且在停止治疗的响应者中持续.
- 味觉障碍与治疗反应无关,并且与特定的咳触发因素相比较少见.
结论:
- 格法皮克桑在RCC的现实环境中表现出快速有效的抗咳作用.
- 这项研究支持fefapixant作为耐火性慢性咳的治疗选择的实用性.
更多相关视频
05:43Establishment of a Mouse Model with Cough Hypersensitivity via Inhalation of Citric Acid
Published on: January 10, 2025
03:25Author Spotlight: Exploring Non-Pharmacological Therapies for Chronic Respiratory Diseases — Linking Intestinal Microbiome Insights to COPD Treatment
Published on: December 27, 2024
相关概念视频
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Medical History
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by...
Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Drugs Used in Upper Respiratory Disorders: Overview
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...